NDA 022315 · Abbvie
Ozurdex
Dexamethasone · Intravitreal · Corticosteroid
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jun 17, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
4,222
936 Phase 3, 495 recruiting
FAERS reports
297,995
251,860 serious, 48,238 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 11, 2026.
OZURDEX is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) 1.1 Retinal Vein Occlusion OZURDEX ® (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). 1.2 Posterior Segment Uveitis OZURDEX is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye. 1.3 Diabetic Macular Edema OZURDEX is indicated for the treatment of diabetic macular edema.
Mechanism: Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 2014 Supplement 9 · Efficacy ReviewLetterLabel
- Sep 24, 2010 Supplement 3 · Efficacy OrphanLabelLetter
- Jun 17, 2009 Original approval · Type 3 - New Dosage Form · priority review ReviewSummary ReviewLetter
1 products under this application
- OZURDEX · DEXAMETHASONE 0.7MG · IMPLANT, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexamethasone" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- The Effect of Cataract Surgery on Sleep QualityPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02593669 · 10,000 participants (planned) · Start Jan 2016 · Primary completion Dec 2018
Drug: Subconjunctival dexamethasone and general anesthesia; Viscoelastic materials · For: Cataract; Sleep
Sites: Guangzhou, China
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use22,933
- fatigue17,499
- diarrhoea17,302
- plasma cell myeloma14,401
- nausea14,181
- pneumonia13,820
- death13,532
- drug ineffective13,296
- neutropenia11,780
- pyrexia11,109
- thrombocytopenia10,774
- dyspnoea10,386
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,561 |
| 2005 | 2,135 |
| 2006 | 1,096 |
| 2007 | 875 |
| 2008 | 1,308 |
| 2009 | 1,923 |
| 2010 | 3,594 |
| 2011 | 5,449 |
| 2012 | 6,776 |
| 2013 | 6,788 |
| 2014 | 8,419 |
| 2015 | 17,458 |
| 2016 | 15,932 |
| 2017 | 17,974 |
| 2018 | 23,448 |
| 2019 | 23,468 |
| 2020 | 25,390 |
| 2021 | 29,153 |
| 2022 | 27,447 |
| 2023 | 24,384 |
| 2024 | 21,709 |
| 2025 | 18,734 |
| 2026 | 12,972 |
Recalls
1 FDA enforcement reports for this application.
Dec 20, 2018 · Class II · Completed
GMP Deviations: A silicone particulate was noted in Ozurdex.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ozurdex (Dexamethasone)
2024 spending
$1.9M
Beneficiaries
622
1,126 claims
Per beneficiary
$3,012
$1,354.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $754,775 |
| 2021 | $762,513 |
| 2022 | $1,505,808 |
| 2023 | $1,927,283 |
| 2024 | $1,873,498 |
Part B: Ozurdex (Dexamethasone) · HCPCS J7312
2024 spending
$48.0M
Beneficiaries
15,038
32,147 claims
Per beneficiary
$3,189
2024 ASP limit $205.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,706,134 |
| 2021 | $51,773,257 |
| 2022 | $52,772,487 |
| 2023 | $50,941,464 |
| 2024 | $47,962,972 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Perioperative Dexamethasone in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials.
Jones IA, LoBasso MA, Wier J, et al. · Anesth Analg 2024 · Systematic Review, Meta-Analysis
- Prophylactic dexamethasone for rebound pain after peripheral nerve block in adult surgical patients: systematic review, meta-analysis, and trial sequential analysis of randomised controlled trials.
Singh NP, Makkar JK, Chawla JK, et al. · Br J Anaesth 2024 · Systematic Review, Meta-Analysis
- Glucocorticoids for croup in children.
Aregbesola A, Tam CM, Kothari A, et al. · Cochrane Database Syst Rev 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis.
Dahan E, El Ghazal N, Nakanishi H, et al. · J Asthma 2023 · Meta-Analysis, Systematic Review
- Dose-response relationships of intravenous and perineural dexamethasone as adjuvants to peripheral nerve blocks: a systematic review and model-based network meta-analysis.
Zufferey PJ, Chaux R, Lachaud PA, et al. · Br J Anaesth 2024 · Systematic Review, Network Meta-Analysis
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, et al. · Lancet 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.